Approval · Notice of Compliance 36780 · 2026
APO-WARFARIN: Notice of Compliance 36780
Issued January 22, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36780
- Date
- January 22, 2026
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter. Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template
- Canadian reference product
- COUMADIN (Dupont Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-WARFARIN | Not yet assigned | — |
Medicinal ingredients
- WARFARIN SODIUM 2 MG per TAB
- WARFARIN SODIUM 1 MG per TAB
- WARFARIN SODIUM 2.5 MG per TAB
- WARFARIN SODIUM 4 MG per TAB
- WARFARIN SODIUM 5 MG per TAB
- WARFARIN SODIUM 10 MG per TAB